Inhibition of a lncRNA for treatment of melanoma

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO RE48801
SERIAL NO

16689648

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITEIT GENT9000 GENT
KATHOLIEKE UNIVERSITEIT LEUVEN K U LEUVEN R&DMINDERBROEDERSSTRAAT 8A BUS 5105 LEUVEN 3000
VIB VZW9052 GENT

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Leucci, Eleonora Linden, BE 3 4
Marine, Jean-Christophe Linden, BE 13 65
Mestdagh, Pieter Bruges, BE 7 4
Vandesompele, Joke Zulte, BE 5 4

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 2, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 May 2, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 2, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00